STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the FDA said ahead of an advisory committee meeting to determine whether the drug should remain on the…
Click here to view original post